TNFRSF6B and ovarian neoplasm: Endogenous DcR3 seems able to increase tumor resistance to chemotherapy, because knockdown of DcR3 dramatically increases sensitivity of pancreatic, gastric and ovarian tumor cells to gemcitabine-[67], 5-fluorouracil- [68], and platinum-induced [69] cell death, respectively.